Dear colleagues, we inform you about the inclusion of a new indication - attention deficit syndrome with hyperactivity (ADHD) in children aged 6 to 12 years, including hyperactivity, impaired attention, impulsiveness.

With the high -speed rhythm of life that is now, many patients, especially working age, do not always manage to find time in their dense schedule for visiting the procedural office. Nevertheless, they also get sick and they can also diagnose serious pathologies that will require the purpose of the course of effective therapy, including Injection forms.

In the “Library” , the “evidence base” posts the article “Results of a multicenter dual blind randomized placebo-controlled clinical study on assessing the effectiveness and safety of the drug Mexidol in the treatment of a deficiency of attention with hyperactivity in children (mega)”.

The results of an international multicenter randomized double-blind-controlled study of the efficiency and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol ^® and Mexidol ^® Forte 250 (study of Memo) conducted in full accordance with the international ethical and scientific research standard and conducting research with the participation Man (GCP), published in the journal of neurology and psychiatry named after S.S. Korsakova, 2021; 121 (11): 7–16., The host of the Higher Attestation Commission - a reviewed publication for neurologists and psychiatrists of Russia.

In order to fully disclose the therapeutic potential of the drug Mexidol ^®, it is consistent long -term therapy (randomized clinical examination of Epica ¹ , 2017): first 14 days of injection (saturation phase), with the subsequent transition to a tablet form of Mexidol ^® or Mexol ^® 250 V. the course of 2 months (phase of maximization of the therapeutic effect). The frequency of therapy is 2-3 times a year or during periods of exacerbations.